Identification of hypermethylated genes associated with cisplatin resistance in human cancers

Xiaofei Chang, Constance L Monitto, Semra Demokan, Myoung Sook Kim, Steven S. Chang, Xiaoli Zhong, Joseph A. Califano, David Sidransky

Research output: Contribution to journalArticle

Abstract

Cisplatin is among the most widely used cytotoxic anticancer agents in solid tumors; however, the development of secondary resistance remains a major obstacle to clinical efficacy. Treatment-related DNA hypermethylation may play a role in creating drug-resistant phenotypes by inactivating genes that are required for cytotoxicity. We applied a pharmacologic unmasking approach to detect hypermethylated genes whose inactivation contributes to cisplatin resistance. Using three pairs of isogeneic, cisplatin-sensitive, and cisplatinresistant cell lines derived from two parental cell lines (KB-3-1 and SCC25), we identified several hundred genes that were downregulated in each resistant cell line and reactivated by the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Among them, 30 genes were common to two or more cell lines and/or reported to be downregulated in previous studies. Bisulfite sequencing confirmed that 14 genes were hypermethylated in resistant cell lines but not in the sensitive parental cell lines. Six of 14 genes (SAT, C8orf4, LAMB3, TUBB, G0S2, and MCAM) were cisplatin inducible in sensitive but not in resistant cell lines. Small interfering RNA knockdown of two genes, SAT and S100P, increased cell viability with cisplatin treatment in sensitive parental cell lines. S100P knockdown significantly decreased the S-phase fraction of parental sensitive cell lines and slowed cell proliferation, which was associated with decreased sensitivity to cisplatin. Based on these findings, we conclude that DNA methylation is a frequent event in cells that are chronically exposed to cisplatin and that methylation-induced gene silencing may play a role in the development of resistance to cytotoxic chemotherapeutic agents.

Original languageEnglish (US)
Pages (from-to)2870-2879
Number of pages10
JournalCancer Research
Volume70
Issue number7
DOIs
StatePublished - Apr 1 2010

Fingerprint

Cisplatin
Cell Line
Genes
Neoplasms
decitabine
Cytotoxins
Gene Silencing
Down-Regulation
Gene Knockdown Techniques
DNA
Methyltransferases
DNA Methylation
S Phase
Antineoplastic Agents
Methylation
Small Interfering RNA
Cell Survival
Cell Proliferation
Phenotype
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Identification of hypermethylated genes associated with cisplatin resistance in human cancers. / Chang, Xiaofei; Monitto, Constance L; Demokan, Semra; Kim, Myoung Sook; Chang, Steven S.; Zhong, Xiaoli; Califano, Joseph A.; Sidransky, David.

In: Cancer Research, Vol. 70, No. 7, 01.04.2010, p. 2870-2879.

Research output: Contribution to journalArticle

Chang, Xiaofei ; Monitto, Constance L ; Demokan, Semra ; Kim, Myoung Sook ; Chang, Steven S. ; Zhong, Xiaoli ; Califano, Joseph A. ; Sidransky, David. / Identification of hypermethylated genes associated with cisplatin resistance in human cancers. In: Cancer Research. 2010 ; Vol. 70, No. 7. pp. 2870-2879.
@article{517c69419f2f48dcb7677b7c0971614d,
title = "Identification of hypermethylated genes associated with cisplatin resistance in human cancers",
abstract = "Cisplatin is among the most widely used cytotoxic anticancer agents in solid tumors; however, the development of secondary resistance remains a major obstacle to clinical efficacy. Treatment-related DNA hypermethylation may play a role in creating drug-resistant phenotypes by inactivating genes that are required for cytotoxicity. We applied a pharmacologic unmasking approach to detect hypermethylated genes whose inactivation contributes to cisplatin resistance. Using three pairs of isogeneic, cisplatin-sensitive, and cisplatinresistant cell lines derived from two parental cell lines (KB-3-1 and SCC25), we identified several hundred genes that were downregulated in each resistant cell line and reactivated by the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Among them, 30 genes were common to two or more cell lines and/or reported to be downregulated in previous studies. Bisulfite sequencing confirmed that 14 genes were hypermethylated in resistant cell lines but not in the sensitive parental cell lines. Six of 14 genes (SAT, C8orf4, LAMB3, TUBB, G0S2, and MCAM) were cisplatin inducible in sensitive but not in resistant cell lines. Small interfering RNA knockdown of two genes, SAT and S100P, increased cell viability with cisplatin treatment in sensitive parental cell lines. S100P knockdown significantly decreased the S-phase fraction of parental sensitive cell lines and slowed cell proliferation, which was associated with decreased sensitivity to cisplatin. Based on these findings, we conclude that DNA methylation is a frequent event in cells that are chronically exposed to cisplatin and that methylation-induced gene silencing may play a role in the development of resistance to cytotoxic chemotherapeutic agents.",
author = "Xiaofei Chang and Monitto, {Constance L} and Semra Demokan and Kim, {Myoung Sook} and Chang, {Steven S.} and Xiaoli Zhong and Califano, {Joseph A.} and David Sidransky",
year = "2010",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-09-3427",
language = "English (US)",
volume = "70",
pages = "2870--2879",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Identification of hypermethylated genes associated with cisplatin resistance in human cancers

AU - Chang, Xiaofei

AU - Monitto, Constance L

AU - Demokan, Semra

AU - Kim, Myoung Sook

AU - Chang, Steven S.

AU - Zhong, Xiaoli

AU - Califano, Joseph A.

AU - Sidransky, David

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Cisplatin is among the most widely used cytotoxic anticancer agents in solid tumors; however, the development of secondary resistance remains a major obstacle to clinical efficacy. Treatment-related DNA hypermethylation may play a role in creating drug-resistant phenotypes by inactivating genes that are required for cytotoxicity. We applied a pharmacologic unmasking approach to detect hypermethylated genes whose inactivation contributes to cisplatin resistance. Using three pairs of isogeneic, cisplatin-sensitive, and cisplatinresistant cell lines derived from two parental cell lines (KB-3-1 and SCC25), we identified several hundred genes that were downregulated in each resistant cell line and reactivated by the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Among them, 30 genes were common to two or more cell lines and/or reported to be downregulated in previous studies. Bisulfite sequencing confirmed that 14 genes were hypermethylated in resistant cell lines but not in the sensitive parental cell lines. Six of 14 genes (SAT, C8orf4, LAMB3, TUBB, G0S2, and MCAM) were cisplatin inducible in sensitive but not in resistant cell lines. Small interfering RNA knockdown of two genes, SAT and S100P, increased cell viability with cisplatin treatment in sensitive parental cell lines. S100P knockdown significantly decreased the S-phase fraction of parental sensitive cell lines and slowed cell proliferation, which was associated with decreased sensitivity to cisplatin. Based on these findings, we conclude that DNA methylation is a frequent event in cells that are chronically exposed to cisplatin and that methylation-induced gene silencing may play a role in the development of resistance to cytotoxic chemotherapeutic agents.

AB - Cisplatin is among the most widely used cytotoxic anticancer agents in solid tumors; however, the development of secondary resistance remains a major obstacle to clinical efficacy. Treatment-related DNA hypermethylation may play a role in creating drug-resistant phenotypes by inactivating genes that are required for cytotoxicity. We applied a pharmacologic unmasking approach to detect hypermethylated genes whose inactivation contributes to cisplatin resistance. Using three pairs of isogeneic, cisplatin-sensitive, and cisplatinresistant cell lines derived from two parental cell lines (KB-3-1 and SCC25), we identified several hundred genes that were downregulated in each resistant cell line and reactivated by the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Among them, 30 genes were common to two or more cell lines and/or reported to be downregulated in previous studies. Bisulfite sequencing confirmed that 14 genes were hypermethylated in resistant cell lines but not in the sensitive parental cell lines. Six of 14 genes (SAT, C8orf4, LAMB3, TUBB, G0S2, and MCAM) were cisplatin inducible in sensitive but not in resistant cell lines. Small interfering RNA knockdown of two genes, SAT and S100P, increased cell viability with cisplatin treatment in sensitive parental cell lines. S100P knockdown significantly decreased the S-phase fraction of parental sensitive cell lines and slowed cell proliferation, which was associated with decreased sensitivity to cisplatin. Based on these findings, we conclude that DNA methylation is a frequent event in cells that are chronically exposed to cisplatin and that methylation-induced gene silencing may play a role in the development of resistance to cytotoxic chemotherapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=77950801864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950801864&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-3427

DO - 10.1158/0008-5472.CAN-09-3427

M3 - Article

VL - 70

SP - 2870

EP - 2879

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 7

ER -